
Avalo Therapeutics (AVTX) Stock Forecast & Price Target
Avalo Therapeutics (AVTX) Analyst Ratings
Bulls say
Avalo Therapeutics is poised for success in future studies with their highly promising abdakibart (potentially BIC anti-IL-1B mAb) treatment for immune-mediated inflammatory diseases such as HS. With their recent acquisition and a diverse pipeline of treatments, including other targeted antibodies, Avalo is well-positioned to cater to the needs of a rapidly growing AI industry. Their recent positive topline results from the Phase II LOTUS study and promising efficacy profile make them a strong contender in the market.
Bears say
Avalo Therapeutics is facing several potential setbacks, as there are risks associated with its product pipeline, potential safety issues, and competition from other biotechnology companies. With revenue heavily dependent on the success of their products in clinical trials and potential regulatory approvals, there is significant uncertainty regarding the company's future financials. Additionally, recent data has shown a decline in the company's stock price, and with a decrease in price target from $35 to $30, it is evident that investors are also skeptical about the company's outlook.
This aggregate rating is based on analysts' research of Avalo Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Avalo Therapeutics (AVTX) Analyst Forecast & Price Prediction
Start investing in Avalo Therapeutics (AVTX)
Order type
Buy in
Order amount
Est. shares
0 shares